Chronic obstructive pulmonary disease (COPD) is characterized by persistent and progressive airflow limitation, and a new study examined the factors responsible for a high St George’s Respiratory Questionnaire for COPD based on severity of airflow limitation.
Chronic obstructive pulmonary disease (COPD) is characterized by persistent and progressive airflow limitation, and a new study examined the factors responsible for a high St George’s Respiratory Questionnaire for COPD (SGRQ-C) based on severity of airflow limitation.
The study, published in the International Journal of COPD, included 1264 patients who were categorized into 2 groups based on the severity of airflow limitation: mild-to-moderate COPD and severe-to-very severe COPD.
“The substantial symptomatic burden of COPD reduces physical and psychological functioning, ultimately decreasing health-related quality of life (HRQoL),” explained the authors.
They sought to analyze the SGRQ-C, which is used to grade symptoms, to identify factors associated with a high score in patients with stable COPD based on the severity of airflow limitation.
The study selected patients in the Korean COPD Subgroup Study cohort and recorded a variety of data, including age, sex, height, weight, smoking status, comorbidities, 6-minute walk distance, cough, sputum, and SGRQ-C score. Of the 902 patients who had mild-to-moderate COPD, 534 (59.2%) had a high SGRQ-C score, and of the 362 patients with severe-to-very severe COPD, 261 (80.4%) had a high SGRQ-C score.
Compared with patients with a low SGRQ-C score, patients with mild-to-moderate COPD and a high score were more likely to be less educated, have more comorbidities, and suffer from more respiratory symptoms, such as cough, sputum, and dyspnea. These patients also had a “significantly lower level” of exercise capacity as determined by the 6-minute walk distance.
Patients with severe-to-very severe COPD and a high score were more likely to have a lower body mass index, a history of pneumonia, osteoporosis, and respiratory symptoms, such as cough, sputum, and dyspnea. Similar to patients with mild-to-moderate COPD, this group had a significantly shorter 6-minute walk distances compared with similar patients with a low SGRQ-C score. No comorbidities were associated with a high score for this group.
Overall, the researchers found a negative correlation between HRQoL and severity of airflow limitation. The fact that only respiratory symptoms were significantly associated with a high SGRQ-C score “indicates the need for an improved management strategy for relieving respiratory symptoms in COPD patients with poor HRQoL,” the authors concluded.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
2 Commerce Drive
Cranbury, NJ 08512